<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes">
    <title>üéß Albuminuria in CKD ‚Äî Audio Edition</title>
    <style>
        :root { --primary: #3b82f6; --primary-light: #60a5fa; --accent: #e07b53; --bg: #1a1a2e; --card-bg: #16213e; --text: #e8e8e8; --text-muted: #a0a0a0; --border: #2d3a4f; }
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); line-height: 1.8; padding: 20px; padding-bottom: 200px; font-size: 18px; }
        .header { text-align: center; padding: 30px 20px; background: linear-gradient(135deg, var(--primary), var(--primary-light)); border-radius: 16px; margin-bottom: 20px; }
        .header h1 { font-size: 1.4rem; margin-bottom: 8px; }
        .header p { opacity: 0.9; font-size: 0.95rem; }
        .audio-controls { position: fixed; bottom: 0; left: 0; right: 0; background: rgba(22,33,62,0.98); padding: 15px 20px; padding-bottom: max(15px, env(safe-area-inset-bottom)); border-top: 1px solid var(--border); z-index: 1000; }
        .controls-row { display: flex; align-items: center; justify-content: center; gap: 15px; margin-bottom: 10px; }
        .control-btn { background: var(--primary); border: none; color: white; width: 50px; height: 50px; border-radius: 50%; font-size: 1.3rem; cursor: pointer; display: flex; align-items: center; justify-content: center; }
        .control-btn.play-btn { width: 65px; height: 65px; font-size: 1.6rem; background: var(--accent); }
        .progress-section { display: flex; align-items: center; gap: 10px; font-size: 0.8rem; color: var(--text-muted); }
        .progress-bar { flex: 1; height: 6px; background: var(--border); border-radius: 3px; cursor: pointer; }
        .progress-fill { height: 100%; background: var(--accent); width: 0%; }
        .current-topic { text-align: center; font-size: 0.85rem; color: var(--accent); margin-top: 8px; }
        .settings-row { display: flex; justify-content: center; gap: 20px; margin-top: 10px; }
        .speed-control select, .pause-control select { background: var(--card-bg); color: var(--text); border: 1px solid var(--border); padding: 6px 10px; border-radius: 8px; }
        .section { background: var(--card-bg); border-radius: 12px; margin-bottom: 20px; }
        .section-header { background: var(--primary); padding: 15px 20px; font-size: 1.1rem; font-weight: 600; display: flex; justify-content: space-between; border-radius: 12px 12px 0 0; }
        .section-content { padding: 20px; }
        .topic { margin-bottom: 20px; }
        .topic-title { font-size: 1rem; font-weight: 600; color: var(--primary-light); margin-bottom: 12px; }
        .content-block { margin-bottom: 12px; padding: 12px 15px; background: rgba(59, 130, 246, 0.1); border-radius: 8px; border-left: 3px solid var(--primary); }
        .content-block.key-point { border-left-color: #f59e0b; background: rgba(245, 158, 11, 0.1); }
        .content-block.clinical { border-left-color: #10b981; background: rgba(16, 185, 129, 0.1); }
        .current { background: rgba(59, 130, 246, 0.3) !important; }
        .voice-selector { margin: 15px 0; padding: 15px; background: var(--card-bg); border-radius: 12px; }
        .voice-selector select { width: 100%; padding: 10px; background: var(--bg); color: var(--text); border: 1px solid var(--border); border-radius: 8px; }
        .toc { background: var(--card-bg); border-radius: 12px; padding: 20px; margin-bottom: 20px; }
        .toc-item { padding: 10px 15px; margin: 5px 0; background: rgba(255,255,255,0.03); border-radius: 8px; cursor: pointer; display: flex; justify-content: space-between; }
        .toc-item.active { background: var(--primary); }
        .source { margin-top: 30px; padding: 15px; background: rgba(255,255,255,0.03); border-radius: 8px; font-size: 0.85rem; color: var(--text-muted); }
    </style>
</head>
<body>
<div class="header">
    <h1>üîµ Albumin, Albuminuria & CKD</h1>
    <p>Therapeutic Modulation Based on KDIGO 2024</p>
    <p style="font-size:0.8rem; opacity:0.8; margin-top:8px;">Audio Edition ‚Ä¢ Nephrology Deep Dive</p>
</div>
<div class="voice-selector"><label>üéôÔ∏è Voice:</label><select id="voiceSelect"></select></div>
<div class="toc"><h2>üìã Chapters</h2>
    <div class="toc-item" data-section="0"><span>1. Definition & Clinical Significance</span><span>~4 min</span></div>
    <div class="toc-item" data-section="1"><span>2. Albuminuria as Mediator of CKD</span><span>~5 min</span></div>
    <div class="toc-item" data-section="2"><span>3. Therapeutic Targets</span><span>~5 min</span></div>
    <div class="toc-item" data-section="3"><span>4. Albumin Infusions</span><span>~2 min</span></div>
    <div class="toc-item" data-section="4"><span>5. Prognostic Utility</span><span>~3 min</span></div>
    <div class="toc-item" data-section="5"><span>6. Practical Teaching Points</span><span>~2 min</span></div>
</div>
<div id="audioContent">

<div class="section" data-section="0">
    <div class="section-header"><span>1. Definition & Clinical Significance</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">What is Albuminuria?</div>
            <div class="content-block">
                <p class="speakable">Albuminuria is defined as abnormal urinary excretion of albumin. It is a marker of glomerular injury and kidney damage.</p>
                <p class="speakable">Normal albuminuria is less than 30 milligrams per gram creatinine on spot urine albumin-to-creatinine ratio.</p>
                <p class="speakable">Moderately increased albuminuria, previously called microalbuminuria, is 30 to 300 milligrams per gram.</p>
                <p class="speakable">Severely increased albuminuria, previously called macroalbuminuria, is greater than 300 milligrams per gram.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">How to Test</div>
            <div class="content-block">
                <p class="speakable">Testing is done with spot urine albumin-to-creatinine ratio, abbreviated ACR.</p>
                <p class="speakable">Confirm abnormal results with 2 to 3 tests over 3 to 6 months before establishing a diagnosis.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Clinical Relevance</div>
            <div class="content-block key-point">
                <p class="speakable">Diagnostically, albuminuria enables early CKD detection, especially in patients with diabetes and hypertension.</p>
                <p class="speakable">Prognostically, albuminuria is an independent predictor of CKD progression, cardiovascular events, and mortality.</p>
                <p class="speakable">Risk rises linearly with albuminuria. Even modest elevations of 10 to 30 milligrams per gram are clinically meaningful.</p>
                <p class="speakable">Higher albuminuria correlates with faster decline in eGFR and higher risk of end-stage renal disease.</p>
                <p class="speakable">Albuminuria also reflects systemic endothelial dysfunction, arterial stiffness, and microvascular injury throughout the body.</p>
            </div>
        </div>
    </div>
</div>

<div class="section" data-section="1">
    <div class="section-header"><span>2. Albuminuria as Mediator of CKD Progression</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Key Concept</div>
            <div class="content-block key-point">
                <p class="speakable">Filtered albumin is not merely a biomarker. It actively drives kidney injury through multiple mechanisms.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Tubular Uptake of Albumin</div>
            <div class="content-block">
                <p class="speakable">Proximal tubular epithelial cells reclaim filtered albumin via megalin-cubilin receptor-mediated endocytosis.</p>
                <p class="speakable">Cubilin binds albumin in the tubular lumen. Megalin facilitates the endocytosis process.</p>
                <p class="speakable">Albumin is then degraded in lysosomes or recycled. The receptors are reused for further uptake.</p>
                <p class="speakable">In the overload scenario, excess filtered albumin saturates this system, leading to tubular stress.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Tubular Inflammatory Response</div>
            <div class="content-block">
                <p class="speakable">Albumin triggers NF-kappa-B activation. NF-kappa-B is a transcription factor that upregulates pro-inflammatory genes.</p>
                <p class="speakable">Tubular cells release MCP-1, which recruits monocytes and macrophages to the interstitium.</p>
                <p class="speakable">They also release RANTES, which recruits T-cells to the area.</p>
                <p class="speakable">Interleukin-6 is released, promoting local immune activation.</p>
                <p class="speakable">TNF-alpha is released, stimulating apoptosis and fibrosis pathways.</p>
                <p class="speakable">Collectively, these mediators recruit immune cells and amplify interstitial inflammation.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Pro-Fibrotic Signaling</div>
            <div class="content-block">
                <p class="speakable">Albumin induces TGF-beta-1 and connective tissue growth factor, abbreviated CTGF.</p>
                <p class="speakable">These factors activate fibroblasts and promote extracellular matrix deposition.</p>
                <p class="speakable">This leads to tubulointerstitial fibrosis, which is a key predictor of progressive CKD.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Oxidative Stress</div>
            <div class="content-block">
                <p class="speakable">Tubular albumin uptake generates reactive oxygen species, or ROS.</p>
                <p class="speakable">These reactive oxygen species further damage tubular cells and propagate the fibrotic process.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Clinical Takeaway</div>
            <div class="content-block key-point">
                <p class="speakable">Persistent albuminuria creates a vicious cycle.</p>
                <p class="speakable">Glomerular injury leads to albuminuria, which causes tubular inflammation, leading to interstitial fibrosis, progressive CKD, and ultimately end-stage renal disease.</p>
                <p class="speakable">Breaking this cycle with therapeutic intervention is essential.</p>
            </div>
        </div>
    </div>
</div>

<div class="section" data-section="2">
    <div class="section-header"><span>3. Therapeutic Targets</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Overview</div>
            <div class="content-block key-point">
                <p class="speakable">Reducing albuminuria slows CKD progression and improves cardiovascular outcomes.</p>
                <p class="speakable">We have multiple drug classes that effectively reduce albuminuria through different mechanisms.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">ACE Inhibitors and ARBs</div>
            <div class="content-block clinical">
                <p class="speakable">ACE inhibitors and ARBs are first-line therapy for albuminuria reduction.</p>
                <p class="speakable">Their mechanism is reducing efferent arteriolar tone, which lowers intraglomerular pressure.</p>
                <p class="speakable">They also have anti-fibrotic and anti-inflammatory effects independent of blood pressure.</p>
                <p class="speakable">ACE inhibitors and ARBs typically achieve 30 to 50 percent reduction in albuminuria.</p>
                <p class="speakable">They have been proven to slow CKD progression in multiple large trials.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">SGLT2 Inhibitors</div>
            <div class="content-block clinical">
                <p class="speakable">SGLT2 inhibitors restore tubuloglomerular feedback and reduce hyperfiltration.</p>
                <p class="speakable">They also have anti-inflammatory and anti-fibrotic effects.</p>
                <p class="speakable">SGLT2 inhibitors achieve approximately 30 percent reduction in albuminuria.</p>
                <p class="speakable">They are effective in both diabetic and non-diabetic CKD based on the DAPA-CKD trial published in the New England Journal of Medicine in 2020.</p>
                <p class="speakable">The effects are additive when combined with ACE inhibitors or ARBs.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Mineralocorticoid Receptor Antagonists</div>
            <div class="content-block clinical">
                <p class="speakable">MRAs such as finerenone and spironolactone block aldosterone effects.</p>
                <p class="speakable">This reduces podocyte injury, inflammation, and fibrosis.</p>
                <p class="speakable">MRAs provide additive benefit when combined with ACE inhibitors or ARBs.</p>
                <p class="speakable">The FIDELIO-DKD and FIGARO-DKD trials demonstrated cardiovascular and renal benefits with finerenone.</p>
                <p class="speakable">When using MRAs, monitor potassium and kidney function closely.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Blood Pressure and Lifestyle</div>
            <div class="content-block">
                <p class="speakable">Optimized blood pressure target is approximately 120 to 130 over 70 to 80 millimeters of mercury.</p>
                <p class="speakable">Sodium restriction enhances response to pharmacologic therapy.</p>
                <p class="speakable">These lifestyle modifications are essential adjuncts to medication.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Mechanistic Summary</div>
            <div class="content-block key-point">
                <p class="speakable">ACE inhibitors and ARBs work hemodynamically by lowering intraglomerular pressure.</p>
                <p class="speakable">SGLT2 inhibitors restore tubuloglomerular feedback and reduce hyperfiltration.</p>
                <p class="speakable">MRAs provide hormone-driven anti-fibrotic and anti-inflammatory effects.</p>
                <p class="speakable">Combining these agents provides maximal renal and cardiovascular protection.</p>
            </div>
        </div>
    </div>
</div>

<div class="section" data-section="3">
    <div class="section-header"><span>4. Albumin Infusions</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Indications</div>
            <div class="content-block">
                <p class="speakable">Albumin infusions are rarely indicated and used only for symptomatic purposes.</p>
                <p class="speakable">In nephrotic syndrome, they can correct severe hypoalbuminemia and enhance diuresis.</p>
                <p class="speakable">In critical illness with hypoalbuminemia, they help maintain oncotic pressure.</p>
                <p class="speakable">After large-volume paracentesis, albumin prevents post-procedure circulatory dysfunction.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Important Note</div>
            <div class="content-block key-point">
                <p class="speakable">Albumin infusion does not alter CKD progression.</p>
                <p class="speakable">It provides only symptomatic benefit and should not be used as disease-modifying therapy.</p>
            </div>
        </div>
    </div>
</div>

<div class="section" data-section="4">
    <div class="section-header"><span>5. Prognostic Utility</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">CKD Progression</div>
            <div class="content-block">
                <p class="speakable">Higher albuminuria predicts faster eGFR decline and increased risk of end-stage renal disease.</p>
                <p class="speakable">This relationship has been confirmed in the CKD Prognosis Consortium meta-analysis published in Lancet in 2010.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Cardiovascular Events</div>
            <div class="content-block">
                <p class="speakable">Albuminuria is strongly associated with myocardial infarction, heart failure, stroke, and cardiovascular mortality.</p>
                <p class="speakable">It serves as a marker of systemic vascular disease beyond kidney-specific risk.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">All-Cause Mortality</div>
            <div class="content-block key-point">
                <p class="speakable">Even low-level albuminuria of 10 to 30 milligrams per gram is predictive of mortality.</p>
                <p class="speakable">This reinforces the importance of screening even when albuminuria is only mildly elevated.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Monitoring Response</div>
            <div class="content-block clinical">
                <p class="speakable">A reduction of 30 percent or more over 6 to 12 months is clinically meaningful.</p>
                <p class="speakable">This reduction guides therapy adjustment and indicates treatment response.</p>
                <p class="speakable">Regular monitoring of albuminuria should be incorporated into CKD management.</p>
            </div>
        </div>
    </div>
</div>

<div class="section" data-section="5">
    <div class="section-header"><span>6. Practical Teaching Points</span><span>üîµ</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Key Takeaways for Residents</div>
            <div class="content-block clinical">
                <p class="speakable">Screen high-risk patients with urine albumin-to-creatinine ratio. High-risk groups include those with diabetes, hypertension, and family history of kidney disease.</p>
                <p class="speakable">Remember that albuminuria is diagnostic, prognostic, AND modifiable. Treat even modest elevations.</p>
                <p class="speakable">Combine ACE inhibitor or ARB, plus SGLT2 inhibitor, plus MRA for maximal renal and cardiovascular protection.</p>
                <p class="speakable">Albumin infusions are symptomatic only. They do not modify disease progression.</p>
                <p class="speakable">Track albuminuria trends over time to guide therapy and risk stratification.</p>
            </div>
        </div>
    </div>
</div>

</div>

<div class="source">
    <strong>References:</strong><br>
    ‚Ä¢ KDIGO 2024 Clinical Practice Guideline for CKD. Kidney Int 2024;105(4S):S117-S314<br>
    ‚Ä¢ Heerspink HJL et al. DAPA-CKD Trial. NEJM 2020;383:1436-1446<br>
    ‚Ä¢ Bakris GL et al. FIDELIO-DKD / FIGARO-DKD Trials. NEJM 2020;383:2219-2229<br>
    ‚Ä¢ CKD Prognosis Consortium meta-analysis. Lancet 2010;375:2073-2081
</div>

<div class="audio-controls">
    <div class="controls-row"><button class="control-btn" onclick="skipBackward()">‚è™</button><button class="control-btn play-btn" id="playPauseBtn" onclick="togglePlayPause()">‚ñ∂Ô∏è</button><button class="control-btn" onclick="skipForward()">‚è©</button><button class="control-btn" onclick="stopReading()">‚èπÔ∏è</button></div>
    <div class="progress-section"><span id="currentTime">0:00</span><div class="progress-bar" onclick="seekTo(event)"><div class="progress-fill" id="progressFill"></div></div><span id="totalTime">0:00</span></div>
    <div class="current-topic" id="currentTopic">Ready to play</div>
    <div class="settings-row"><div class="speed-control"><label>Speed:</label><select id="speedSelect" onchange="updateSpeed()"><option value="0.75">0.75√ó</option><option value="1" selected>1√ó</option><option value="1.5">1.5√ó</option><option value="2">2√ó</option></select></div><div class="pause-control"><label>Pauses:</label><select id="pauseSelect" onchange="updatePauses()"><option value="short">Short</option><option value="medium" selected>Medium</option><option value="long">Long</option></select></div></div>
</div>
<script>
let isPlaying=false,currentSentenceIndex=0,sentences=[],speechRate=1,englishVoices=[],pauseSettings={sentence:400,paragraph:800,section:1500};
document.addEventListener('DOMContentLoaded',()=>{loadVoices();buildSentenceList();setupTOC();const s=localStorage.getItem('albumin_audio_pos');if(s)currentSentenceIndex=parseInt(s)||0;});
function loadVoices(){const sel=document.getElementById('voiceSelect');function pop(){const all=speechSynthesis.getVoices();englishVoices=all.filter(v=>v.lang.startsWith('en-'));if(!englishVoices.length){setTimeout(pop,100);return;}sel.innerHTML='';englishVoices.forEach((v,i)=>{const o=document.createElement('option');o.value=i;o.textContent=`${v.localService?'‚≠ê ':''}${v.name}`;sel.appendChild(o);});}pop();speechSynthesis.onvoiceschanged=pop;}
function buildSentenceList(){sentences=[];document.querySelectorAll('.speakable').forEach((el,i,arr)=>{const sec=el.closest('.section'),top=el.closest('.topic');sentences.push({text:el.textContent.trim(),element:el,section:sec?parseInt(sec.dataset.section):0,topic:top?.querySelector('.topic-title')?.textContent||'',isNewBlock:i===0||el.closest('.content-block')!==arr[i-1]?.closest('.content-block'),isNewSection:i===0||(sec?.dataset.section!==arr[i-1]?.closest('.section')?.dataset.section)});});updateProgress();}
function setupTOC(){document.querySelectorAll('.toc-item').forEach(item=>{item.addEventListener('click',()=>jumpToSection(parseInt(item.dataset.section)));});}
function jumpToSection(idx){const i=sentences.findIndex(s=>s.section===idx);if(i!==-1){currentSentenceIndex=i;if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}}
function togglePlayPause(){isPlaying?pauseReading():startReading();}
function startReading(){isPlaying=true;document.getElementById('playPauseBtn').textContent='‚è∏Ô∏è';speakCurrentSentence();}
function pauseReading(){isPlaying=false;speechSynthesis.cancel();document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';localStorage.setItem('albumin_audio_pos',currentSentenceIndex);}
function stopReading(){isPlaying=false;speechSynthesis.cancel();currentSentenceIndex=0;document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';updateProgress();localStorage.removeItem('albumin_audio_pos');}
function speakCurrentSentence(){if(!isPlaying||currentSentenceIndex>=sentences.length){if(currentSentenceIndex>=sentences.length)stopReading();return;}const s=sentences[currentSentenceIndex],u=new SpeechSynthesisUtterance(s.text),vi=parseInt(document.getElementById('voiceSelect').value)||0;if(englishVoices[vi])u.voice=englishVoices[vi];u.lang='en-US';u.rate=speechRate;document.querySelectorAll('.current').forEach(el=>el.classList.remove('current'));s.element.classList.add('current');s.element.scrollIntoView({behavior:'smooth',block:'center'});document.getElementById('currentTopic').textContent=s.topic;updateProgress();u.onend=()=>{currentSentenceIndex++;if(currentSentenceIndex<sentences.length){let p=pauseSettings.sentence;if(sentences[currentSentenceIndex].isNewSection)p=pauseSettings.section;else if(sentences[currentSentenceIndex].isNewBlock)p=pauseSettings.paragraph;setTimeout(()=>{if(isPlaying)speakCurrentSentence();},p);}else stopReading();};speechSynthesis.speak(u);}
function updateProgress(){const pct=sentences.length?(currentSentenceIndex/sentences.length)*100:0;document.getElementById('progressFill').style.width=pct+'%';const avg=3/speechRate;document.getElementById('currentTime').textContent=Math.floor(currentSentenceIndex*avg/60)+':'+(Math.floor(currentSentenceIndex*avg)%60).toString().padStart(2,'0');document.getElementById('totalTime').textContent=Math.floor(sentences.length*avg/60)+':'+(Math.floor(sentences.length*avg)%60).toString().padStart(2,'0');}
function seekTo(e){currentSentenceIndex=Math.floor((e.offsetX/e.currentTarget.offsetWidth)*sentences.length);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipForward(){currentSentenceIndex=Math.min(currentSentenceIndex+10,sentences.length-1);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipBackward(){currentSentenceIndex=Math.max(currentSentenceIndex-10,0);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function updateSpeed(){speechRate=parseFloat(document.getElementById('speedSelect').value);updateProgress();}
function updatePauses(){const s=document.getElementById('pauseSelect').value;pauseSettings=s==='short'?{sentence:200,paragraph:400,section:800}:s==='long'?{sentence:600,paragraph:1200,section:2000}:{sentence:400,paragraph:800,section:1500};}
</script>
</body>
</html>
